乙型肝炎核心抑制剂ABI-H0731与核苷酸（t）逆转录酶抑制剂联

StephenW

                                                                                                                                                                                                                                                                                              

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg negative chronic hepatitis B infection
	EASL 2020 virtual Aug 27-29 Reported by Jules Levin Scott Fung1, Mark S. Sulkowski2, Jacob Lalezari3, Eugene R. Schiff4, Douglas Dieterich5, Tarek Hassanein6, Paul Kwo7, Magdy Elkhashab8, Ronald Nahass9, Walid Ayoub10, Steven-Huy Han11, Maurizio Bonacini3, Katia Alves12, Hany Zayed12, Qi Huang12, Richard Colonno12, Steven J Knox12, Luisa M. Stamm12, Alnoor Ramji13, Michael Bennett14, Edward Gane15, Natarajan Ravendhran16, James Park17, Ira Jacobson17, Ho Bae18, Sing Chan19, Hie-Won Hann20, Xiaoli Ma21, Tuan T. Nguyen22, Man-Fung Yuen23 1University of Toronto, Toronto, Canada; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Quest Clinical Research, San Francisco, CA, US; 4Schiff Center for Liver Diseases, University of Miami School of Medicine, Miami, FL, US; 5Department of Medicine, Division of Liver Diseases, Icahn School of Medicine, Mount Sinai Hospital, New York, NY, US; 6Southern California Research Center, Coronado, CA, US; 7Stanford University Medical Center, Stanford, CA, US; 8Toronto Liver Centre, Toronto, ON, Canada; 9Infectious Disease Care, Hillsborough, FL, US; 10Cedars-Sinai Medical Center, Los Angeles, CA, US; 11Pfleger Liver Institute, Universityof California, Los Angeles, CA, US; 12Assembly Biosciences, Inc., South San Francisco, CA, US; 13Providence Health Care Research Institute, Vancouver, BC, Canada; 14Medical Associates Research Group, San Diego, CA, US; 15Auckland Clinical Studies Ltd, Auckland, New Zealand; 16Digestive Disease Associates, Catonsville, MD, US; 17New York University Langone Medical Center, New York, NY, US; 18Asian Pacific Liver Center, Los Angeles, CA, US; 19Sing Chan MD, New York, NY, US; 20Thomas Jefferson University Hospital, Philadelphia, PA, US; 21Office of Xiaoli Ma, Philadelphia, PA, US; 22T Nguyen Research and Education, Inc., San Diego, CA, US; 23Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong

windu

有一例出现反弹？什么情况？

乙肝人1949

啥啥啥，能有翻译不？Pp丅做的不错

StephenW

回复 windu 的帖子

"one patient experienced hbvdna rebound (1 log increase from nadir) in the setting of non-compliance with both study drugs"

一名患者经历了hbvdna反弹（从最低点增加了1 log）, 在两种药物均未依从的情况下.

windu

未依从，原谅我没看到，如果这样的话，证明0731的停药理论有可能成功

windu

HBsAg即使缓慢，但能够持续下降，关键是核心抗原HBcrAg也下降，可以期待

windu

停药半年没有反弹，不错

左罗

windu 发表于 2020-9-26 20:24
停药半年没有反弹，不错

“未依从，原谅我没看到，如果这样的话，证明0731的停药理论有可能成功”

        非常期待这样的神药诞生，继续吧，祝福好运！